Fibralign Corp.

Union City,  CA 
United States
  • Booth: 441

Fibralign Corporation is a Stanford University spin-out biotech company that produces novel therapeutic medical devices to address major unmet medical needs. The Company is in commercial sales in the US with its first product, the BioBridge® Collagen Matrix. BioBridge’s first target is treatment and prevention of Secondary Lymphedema, a global chronic disease that currently has no cure. Clinical benefit has already been demonstrated and a Stanford-led multi-site clinical study is currently underway for breast cancer-related lymphedema (funded by an NCI SBIR bridge grant).

For technical assistance with this webpage, please contact support